Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
Zhou
Jin
J
Department of Hematology, the First Hospital of Harbin Medical University. jinzhouh85@163.com
Meng
Ran
R
Yang
Bao-feng
BF
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage* / Q000009:adverse effects; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D007964:Leukocytosis / Q000139:chemically induced; D010087:Oxides / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide